The AstraZeneca share price is rising fast. Here’s what I’d do now

FTSE 100 pharmaceuticals giant AstraZeneca turned in a good set of results. Is it time to buy right now?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 pharmaceuticals giant AstraZeneca (LSE: AZN) share price was a big gainer yesterday, rising by 5.5% from the day before as it reported a healthy set of results. Its share price is now close to all-time highs, raising the question – Is this a good time to buy AZN?

Expensive but worthy

I find it helpful to look at the price-to-earnings ratio (P/E) when share prices are rising to get a sense of how expensive the stock really is. From the looks of it, AZN sure is highly priced. Its 12-month trailing P/E is almost 43x compared to 19x for another FTSE 100 pharmaceuticals peer GlaxoSmithKline (GSK). Not to undermine GSK’s value, but I think this is a case of investors putting a premium on AZN rather than a one-off spike in its P/E, considering that it’s been maintained for some time now.

It was my top share for May, after it reported a good set of numbers and my sense was that it would rise from there on. From the time the article was published to now, the share price is up 31% and interestingly enough, the P/E is actually marginally lower than the 45x seen then. As an investor, this tells me that there are capital gains to be made even if the ratio is high, instructive as it is. Also, a high ratio doesn’t indicate that the share price will come off soon. In other words, don’t let a high P/E deter you right now because there are enough reasons that still make AZN attractive.  

Safe haven

It’s a big pharmaceuticals company in an economic environment that continues to look uncertain. A number of other defensive shares have also seen a great run-up in share prices in recent years and AZN is no exception. Its international focus also helps, since it’s not entirely vulnerable to the UK’s fortunes. In the latest earnings release, CEO Pascal Soriot noted “impressive results” in international markets like China, the US and Japan.

Performance boost

Besides this, yesterday’s results showed an 18% increase in product sales at constant exchange rate and core operating profit grew by 41% in the third quarter of 2019. The numbers look good on a year-to-date basis too. I also like that AZN has actually upgraded its sales guidance for the second straight quarter, which basically means that it is expected to continue performing going forward.

Coming back to the original question – should I buy AZN shares now, even with the price rise? I reckon that its share price will rise higher over time if things continue to go the way they are right now. Since we at the Motley Fool are concerned with long-term investments, now is as good a time as any other to buy the share. As is the nature of share prices, there will most likely be short-term dips in the near future, and that should be an opportunity to buy more of AZN. But some can be bought right away, I believe.

Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Lady wearing a head scarf looks over pages on company financials
Investing Articles

Is April a good time to start buying shares?

Wondering whether now's a good time to start buying shares to build wealth? History suggests it is, says Edward Sheldon.

Read more »

A senior group of friends enjoying rowing on the River Derwent
Investing Articles

How much passive income could a Stocks and Shares ISA pump out every year?

Regular investing inside a Stocks and Shares ISA could lead to the equivalent of £141 a week in tax-free passive…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

With the FTSE 100 down 5%+ investors should remember this legendary quote from Warren Buffett

Warren Buffett is widely regarded as the greatest investor of all time. And he says that the best time to…

Read more »

Inflation in newspapers
Investing Articles

1 FTSE 100 stock that could benefit from higher inflation

For most companies, inflation is a risk. But for one FTSE 100 firm, higher input costs could be an opportunity…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

The 2026 stock market sell-off could be a rare opportunity to build wealth in an ISA

The recent stock market sell-off has led to some shares falling 20% or more. This could be a great opportunity…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

It’s down another 13%! Analysts were dead wrong about the Greggs share price

The Greggs share price continues to fall and analysts have been revising their share price targets down further. Dr James…

Read more »

Burst your bubble thumbtack and balloon background
Investing Articles

Is the stock market about to reach breaking point?

Private credit has a problem with the emergence of artificial intelligence. And it could be set to create issues across…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

A once-in-a-decade chance to buy this S&P 500 stock?

As investors focus on oil prices and the conflict in Iran, Stephen Wright's looking at potential opportunities in the S&P…

Read more »